Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
- PMID: 31122893
- DOI: 10.1016/S2213-2600(19)30172-9
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
Abstract
Background: Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a recombinant human pentraxin 2 protein, in a phase 2 double-blind, randomised controlled trial had significantly reduced decline in percentage of predicted forced vital capacity (FVC) and stabilised 6-min walking distance compared with placebo over a 28-week period. Here we report the 76-week results of an open-label extension study.
Methods: Patients who completed the 28-week double-blind period of the PRM-151-202 trial were eligible to participate in the open-label extension study. Patients previously enrolled in the PRM-151 group continued this treatment and those previously in the placebo group crossed over to PRM-151. All patients received PRM-151 in 28-week cycles with loading doses of 10 mg/kg by 60 min intravenous infusions on days 1, 3, and 5 in the first week of each cycle followed by one infusion of 10 mg/kg every 4 weeks. The primary objective of the open-label extension study was to assess the long-term safety and tolerability of PRM-151, which were assessed by analysing adverse events (AEs) up to week 76 in all patients who received at least one dose of PRM-151 during the open-label extension study. Exploratory efficacy analyses were done by assessing changes from baseline in percentage of predicted FVC and 6-min walking distance, with descriptive statistics to week 76 and with random-intercept mixed models to week 52. This study is registered with ClinicalTrials.gov, number NCT02550873, and with EudraCT, number 2014-004782-24.
Findings: Of 116 patients who completed the double-blind treatment period, 111 entered the open-label extension study (74 from the PRM-151 group and 37 from the placebo group). 84 (76%) of 111 patients received concomitant IPF therapy (pirfenidone n=55 or nintedanib n=29). AEs were consistent with long-term IPF sequelae. 31 (28%) patients had serious AEs. Those occurring in two or more patients were pneumonia (six [5%] of 111), IPF exacerbation (four [4%]), IPF progression (four [4%]), and chest pain (two [2%]). 21 (19%) patients had severe AEs, of which IPF exacerbation and IPF progression each occurred in two (2%) patients. Two (2%) patients experienced life-threatening AEs (one had pneumonia and one had small-cell lung cancer extensive stage). A persistent treatment effect was observed for PRM-151 in patients who continued treatment, with a decline in percentage of predicted FVC of -3·6% per year and in 6-min walking distance of -10·5 m per year at week 52. In patients who started PRM-151 during the open-label extension study, compared with the slopes for placebo, decline reduced for percentage of predicted FVC (from -8·7% per year in weeks 0-28 to -0·9% per year in weeks 28-52, p<0·0001) and 6-min walking distance (from -54·9 m per year to -3·5 m per year, p=0·0224).
Interpretation: Long-term treatment with PRM-151 was well tolerated and the effects on percentage of predicted FVC and 6-min walking distance were persistent on continuation and positive in patients who crossed over from placebo. These findings support further study of PRM-151 in larger populations of patients with IPF.
Funding: Promedior.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
Human pentraxin 2 protein treatment for IPF.Lancet Respir Med. 2019 Aug;7(8):640-641. doi: 10.1016/S2213-2600(19)30173-0. Epub 2019 May 20. Lancet Respir Med. 2019. PMID: 31122900 No abstract available.
Similar articles
-
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129. JAMA. 2018. PMID: 29800034 Free PMC article. Clinical Trial.
-
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.Respir Res. 2022 May 21;23(1):129. doi: 10.1186/s12931-022-02047-0. Respir Res. 2022. PMID: 35597980 Free PMC article. Clinical Trial.
-
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Respir Med. 2016 Jun;4(6):445-53. doi: 10.1016/S2213-2600(16)30044-3. Epub 2016 May 5. Lancet Respir Med. 2016. PMID: 27161257 Clinical Trial.
-
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.Eur Respir Rev. 2012 Jun 1;21(124):161-7. doi: 10.1183/09059180.00001112. Eur Respir Rev. 2012. PMID: 22654089 Free PMC article. Review.
-
Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.Drugs. 2015 Feb;75(2):219-30. doi: 10.1007/s40265-015-0350-9. Drugs. 2015. PMID: 25604027 Review.
Cited by
-
Unraveling the mechanism of ethyl acetate extract from Prismatomeris connata Y. Z. Ruan root in treating pulmonary fibrosis: insights from bioinformatics, network pharmacology, and experimental validation.Front Immunol. 2024 Jan 8;14:1330055. doi: 10.3389/fimmu.2023.1330055. eCollection 2023. Front Immunol. 2024. PMID: 38259493 Free PMC article.
-
Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages.Antioxidants (Basel). 2023 Nov 21;12(12):2022. doi: 10.3390/antiox12122022. Antioxidants (Basel). 2023. PMID: 38136142 Free PMC article.
-
Novel Selective Quantification of Zinpentraxin Alfa Biotherapeutic in the Presence of Endogenous Isomer in Plasma Samples of Idiopathic Pulmonary Fibrosis Patients Using Immunoaffinity LC-MS.AAPS J. 2023 Dec 19;26(1):9. doi: 10.1208/s12248-023-00878-3. AAPS J. 2023. PMID: 38114736
-
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Drugs. 2023 Nov;83(17):1581-1593. doi: 10.1007/s40265-023-01950-0. Epub 2023 Oct 26. Drugs. 2023. PMID: 37882943 Free PMC article. Review.
-
Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.Cancers (Basel). 2023 Aug 29;15(17):4323. doi: 10.3390/cancers15174323. Cancers (Basel). 2023. PMID: 37686599 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases